Physician profile
Mark B Silverman
NPI 1336147958
$225,488.35
in general payments reported to CMS, 2019-2025
73 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $37K · 2021: $28K · 2022: $31K · 2023: $20K · 2024: $26K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $14K · Consulting Fee: $9,610 · Travel and Lodging: $4,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,163.00 |
| Food and Beverage | $13,810.86 |
| Consulting Fee | $9,609.50 |
| Travel and Lodging | $4,473.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $121,678.10 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Genzyme Corporation | $43,604.01 | 2019-2025 | |
| Emd Serono, INC. | $18,537.77 | 2019-2025 | Mavenclad, Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $12,673.14 | 2020-2025 | Zeposia |
| Celgene Corporation | $9,064.52 | 2021-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $2,454.68 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,512.16 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ucb, INC. | $1,428.40 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $1,352.95 | 2019-2025 | Ubrelvy, Botox, Qulipta |
| Neurocrine Biosciences, INC. | $969.91 | 2019-2025 | Ingrezza, Ongentys |
| Tg Therapeutics, INC. | $956.52 | 2023-2025 | |
| Csl Behring | $835.94 | 2019-2025 | Hizentra |
| Eisai INC. | $711.37 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $620.04 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $589.85 | 2022-2025 | Hyqvia |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $524.88 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $500.57 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $429.46 | 2019-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $428.16 | 2019-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $364.17 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Lilly USA, LLC | $360.68 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Mdd US Operations, LLC | $342.50 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $325.34 | 2023-2024 | Aptiom |
| Vanda Pharmaceuticals INC. | $286.61 | 2024-2025 | Ponvory |
| Sk Life Science, INC. | $265.32 | 2020-2025 | |
| Avanir Pharmaceuticals, INC. | $265.06 | 2019-2022 | |
| Kyowa Kirin, INC. | $225.79 | 2019-2024 | Nourianz |
| Neurelis, INC. | $225.54 | 2020-2025 | Valtoco |
| Acorda Therapeutics, INC | $224.66 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $212.82 | 2022-2025 | Firdapse |
| Adamas Pharmaceuticals, INC. | $209.21 | 2019-2021 | |
| Grifols USA, LLC | $196.13 | 2019-2022 | |
| Pfizer INC. | $180.24 | 2021-2025 | |
| Horizon Therapeutics Plc | $178.88 | 2021-2023 | Uplizna |
| Alnylam Pharmaceuticals INC. | $169.98 | 2019-2025 | Onpattro, Amvuttra |
| Boston Scientific Corporation | $165.44 | 2020 | |
| Corium, LLC | $149.34 | 2023 | Adlarity |
| Allergan, INC. | $146.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $134.67 | 2021-2025 | Andexxa, Wainua |
| Merz Pharmaceuticals, LLC | $130.05 | 2023-2025 | Xeomin, Ampyra, Inbrija |
| Jazz Pharmaceuticals INC. | $124.54 | 2022-2025 | |
| Octapharma USA, INC. | $104.83 | 2023-2024 | Panzyga |
| Argenx US, INC. | $102.96 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Sunovion Pharmaceuticals INC. | $99.05 | 2019-2022 | |
| Banner Life Sciences, LLC | $96.29 | 2021-2022 | |
| Aucta Pharmaceuticals, INC. | $93.62 | 2024-2025 | Motpoly Xr |
| Livanova USA, INC. | $88.28 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceuticals, INC. | $84.19 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $81.39 | 2022 | |
| Akcea Therapeutics, INC. | $76.68 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $76.59 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $74.29 | 2019-2022 | |
| Zogenix INC. | $66.44 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $62.33 | 2023-2025 | Rexulti, Nuedexta |
| Cycle Pharmaceuticals INC | $57.94 | 2025 | Tascenso Odt, Bafiertam |
| Tanabe Pharma America, INC. | $51.69 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $50.51 | 2025 | Keveyis |
| Janssen Biotech, INC. | $45.78 | 2025 | |
| Amneal Pharmaceuticals LLC | $45.66 | 2022-2024 | Rytary |
| Cala Health, INC. | $42.50 | 2022-2023 | Cala Trio |
| Bausch Health US, LLC | $40.07 | 2019 | |
| Ani Pharmaceuticals, INC. | $39.84 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $39.41 | 2024 | Acthar |
| Hospira, INC. | $37.16 | 2024-2025 | |
| Nevro Corp. | $32.68 | 2022 | |
| Grt US Holding, INC. | $25.26 | 2021-2022 | |
| Averitas Pharma INC. | $18.65 | 2023 | Qutenza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.72 | 2023 | Rexulti |
| Invivyd INC | $17.25 | 2025 | Pemgarda |
| Collegium Pharmaceutical, INC. | $17.18 | 2022 | |
| Ge Healthcare | $16.94 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.78 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $14.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.